PhRMA's new re­port counts each can­cer drug in the US pipeline, which has now swelled to over 1,000 in the clin­ic

Can­cer drugs are crowd­ing in to an al­ready cramped pipeline this year, with hun­dreds of im­muno-on­col­o­gy hope­fuls now tak­ing a shot at clin­i­cal test­ing. That …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER